Kantola Kalle, Hedman Lea, Allander Tobias, Jartti Tuomas, Lehtinen Pasi, Ruuskanen Olli, Hedman Klaus, Söderlund-Venermo Maria
Department of Virology, Haartman Institute, University of Helsinki, Finland.
Clin Infect Dis. 2008 Feb 15;46(4):540-6. doi: 10.1086/526532.
A new human-pathogenic parvovirus, human bocavirus (HBoV), has recently been discovered and associated with respiratory disease in small children. However, many patients have presented with low viral DNA loads, suggesting HBoV persistence and rendering polymerase chain reaction-based diagnosis problematic. Moreover, nothing is known of HBoV immunity. We examined HBoV-specific systemic B cell responses and assessed their diagnostic use in young children with respiratory disease.
Paired serum samples from 117 children with acute wheezing, previously studied for 16 respiratory viruses, were tested by immunoblot assays using 2 recombinant HBoV capsid antigens: the unique part of virus protein 1 and virus protein 2.
Virus protein 2 was superior to the unique part of virus protein 1 with respect to immunoreactivity. According to the virus protein 2 assay, 24 (49%) of 49 children who were positive for HBoV according to polymerase chain reaction had immunoglobulin (Ig) M antibodies, 36 (73%) had IgG antibodies, and 29 (59%) exhibited IgM antibodies and/or an increase in IgG antibody level. Of 22 patients with an increase in antibody levels, 20 (91%) had a high load of HBoV DNA in the nasopharynx, supporting the hypothesis that a high HBoV DNA load indicates acute primary infection, whereas a low load seems to be of less clinical significance. In a subgroup of patients who were previously determined to have acute HBoV infection (defined as a high virus load in the nasopharynx, viremia, and absence of other viral infections), 9 (100%) of 9 patients had serological evidence of primary infection. In the control group of 68 children with wheezing who had polymerase chain reaction results negative for HBoV in the nasopharynx, 9 (13%) had IgM antibodies, including 5 who displayed an increase in IgG antibody levels and were viremic. No cross-reactivity with human parvovirus B19 was detected.
Respiratory infections due to HBoV are systemic, elicit B cell immune responses, and can be diagnosed serologically. Serological diagnoses correlate with high virus loads in the nasopharynx and with viremia. Serological testing is an accurate tool for disclosing the association of HBoV infection with disease.
一种新的人类致病性细小病毒,人博卡病毒(HBoV),最近被发现并与幼儿呼吸道疾病相关。然而,许多患者的病毒DNA载量较低,提示HBoV持续存在,这使得基于聚合酶链反应的诊断存在问题。此外,对HBoV免疫情况尚无了解。我们检测了HBoV特异性全身B细胞反应,并评估其在患有呼吸道疾病幼儿中的诊断价值。
对117例急性喘息儿童的配对血清样本进行检测,这些样本之前已针对16种呼吸道病毒进行过研究,采用免疫印迹法,使用2种重组HBoV衣壳抗原:病毒蛋白1的独特部分和病毒蛋白2。
就免疫反应性而言,病毒蛋白2优于病毒蛋白1的独特部分。根据病毒蛋白2检测,在49例经聚合酶链反应检测HBoV呈阳性的儿童中,24例(49%)有免疫球蛋白(Ig)M抗体,36例(73%)有IgG抗体,29例(59%)同时有IgM抗体和/或IgG抗体水平升高。在22例抗体水平升高的患者中,20例(91%)鼻咽部HBoV DNA载量高,支持了高HBoV DNA载量提示急性原发性感染,而低载量临床意义较小这一假说。在先前被确定为急性HBoV感染(定义为鼻咽部病毒载量高、病毒血症且无其他病毒感染)的患者亚组中,9例患者中有9例(100%)有原发性感染的血清学证据。在68例喘息儿童的对照组中,其鼻咽部聚合酶链反应检测HBoV结果为阴性,9例(13%)有IgM抗体,其中5例IgG抗体水平升高且有病毒血症。未检测到与人细小病毒B19的交叉反应。
HBoV引起的呼吸道感染是全身性的,可引发B细胞免疫反应,且可通过血清学诊断。血清学诊断与鼻咽部高病毒载量及病毒血症相关。血清学检测是揭示HBoV感染与疾病关联的准确工具。